Skip to main content
. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533

Figure 2.

Figure 2

Activity of NK-92/5.28.z against ErbB2-expressing breast carcinoma cells. Cytotoxicity of CAR-engineered ErbB2-specific NK-92/5.28.z cells (filled circles) against ErbB2-overexpressing and trastuzumab-sensitive MDA-MB453 (left), or ErbB2-overexpressing and trastuzumab-resistant JIMT-1 (middle) and CAL-51 (right) breast carcinoma cells was investigated in flow cytometry-based cytotoxicity assays after coincubation of NK cells and tumor cells at different effector to target ratios (E/T) for 2 h. Parental NK-92 cells were included for comparison (open circles). Mean values ± SEM are shown; n = 3.